Psychopharmacologic Treatment of Schizophrenia in Adolescents and Children

被引:12
|
作者
Lee, Esther S. [1 ]
Kronsberg, Hal [1 ]
Findling, Robert L. [1 ]
机构
[1] Johns Hopkins Univ, Sch Med, Div Child & Adolescent Psychiat, Dept Psychiat & Behav Sci,Bloomberg Childrens Ctr, 1800 Orleans St,Suite 12344, Baltimore, MD 21287 USA
基金
美国国家卫生研究院;
关键词
Adolescents; Antipsychotic medication; Antipsychotic side effects; Children; Psychopharmacology; Psychosis; Schizophrenia; INDUCED WEIGHT-GAIN; PALIPERIDONE EXTENDED-RELEASE; EARLY-ONSET SCHIZOPHRENIA; ACTING INJECTABLE ANTIPSYCHOTICS; DOUBLE-BLIND; 2ND-GENERATION ANTIPSYCHOTICS; OPEN-LABEL; PROLACTIN LEVELS; MAINTENANCE TREATMENT; SPECTRUM DISORDERS;
D O I
10.1016/j.chc.2019.08.009
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
An increasing number of antipsychotic medications have demonstrated efficacy in randomized placebo-controlled trials in the treatment of children and adolescents with schizophrenia. This review summarizes and synthesizes relevant antipsychotic medication studies, with particular emphasis on second-generation agents, and discusses other clinical considerations that may influence medication selection. With the exception of clozapine demonstrating superior efficacy in the improvement of psychotic symptoms in treatment-resistant patients, many antipsychotic agents have been shown to be similarly efficacious, including first-generation medications. Consideration of the side-effect profile, which can differ substantially from medication to medication, is essential when choosing treatment options.
引用
收藏
页码:183 / +
页数:29
相关论文
共 50 条